Walgreens Boots Alliance Earnings Preview: Pharmacy Strength vs. Retail Weakness
Walgreens Boots Alliance (WBA) faces a pivotal moment as it prepares to report Q3 2025 earnings on June 26. Analysts project $0.33 EPS and $36.8 billion revenue—a marginal 0.9% year-over-year sales increase but a sharp decline from last quarter's $0.63 EPS. The U.S. pharmacy segment remains the engine of growth, buoyed by branded drug inflation and prescription volume, while front-end retail sales continue to lag.
Investors are weighing whether pharmacy performance can offset broader challenges. The company's turnaround strategy—store closures, healthcare focus, and a potential Sycamore Partners buyout—adds layers of uncertainty. With full-year guidance withdrawn, the earnings call may reveal more about structural changes than quarterly metrics.